In the liver, GH is the major stimulator of IGF-1, and the downstream effects of IGF-1 include reducing visceral fat, lipogenesis, triglyceride accumulation, and improving insulin resistance to inhibit the development of MASLD [71]. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.